Linkedin Facebook Twitter Youtube

19 Jul Anocca

Posted at 18:03h in by

Reagan Jarvis, Ph.D., CEO

Oct. 7 | 5:30pm | FLW Ballroom F

Södertälje, Sweden

(Private)

Anocca leverages its deep-tech cell-based platform and in-house cGMP capability to discover, develop and manufacture novel TCR-T product libraries at scale for the treatment of solid tumor cancers and other serious diseases, including autoimmune and infectious disease. 
The company’s oncology pipeline comprises over 40 high value TCR-T assets that span a wide range of cancer targets and HLA restrictions. The most advanced TCR-T progam, targeting KRAS G12V in pancreatic cancer is starting a phase 1/2a trial in Europe, following CTA approval in March 2025. 
Based near Stockholm in Sweden, Anocca is privately held and employs a team of over 130 talented individuals. 

www.anocca.com 



About the Event

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 110+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 1,500 attendees – over 30% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Dates & Location

October 5-7, 2026
Arizona Biltmore
Phoenix, AZ

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions